# Mario Mandalà

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/mario-mandala/

## Facts

| Field | Value |
| --- | --- |
| Citations | 40,466 |
| Field | Melanoma and MAPK Pathways |
| h-index | 78 |
| i10-index | 260 |
| Last Known Institution | University of Perugia |
| OpenAlex ID | https://openalex.org/A5010492722 |
| ORCID iD | https://orcid.org/0000-0001-8846-8959 |
| Works | 525 |

## Researcher papers

- [Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma](https://scholariq.org/papers/adjuvant-pembrolizumab-versus-placebo-in-resected-stage-iii-melanoma/)
- [2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer](https://scholariq.org/papers/2019-international-clinical-practice-guidelines-for-the-treatment-and/)
- [Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study](https://scholariq.org/papers/nadroparin-for-the-prevention-of-thromboembolic-events-in-ambulatory-patients/)
- [Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial](https://scholariq.org/papers/adjuvant-nivolumab-versus-ipilimumab-in-resected-stage-iiib-c-and-stage-iv/)
- [Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial](https://scholariq.org/papers/adjuvant-pembrolizumab-versus-placebo-in-resected-stage-iii-melanoma-eortc-1325/)
- [Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility](https://scholariq.org/papers/genome-wide-association-meta-analyses-combining-multiple-risk-phenotypes-provide/)
- [ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee](https://scholariq.org/papers/esmo-consensus-conference-recommendations-on-the-management-of-metastatic/)

## Researcher topics

- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Venous Thromboembolism Diagnosis and Management](https://scholariq.org/topics/venous-thromboembolism-diagnosis-and-management-2/)

## Researcher university

- [University of Perugia](https://scholariq.org/institutions/university-of-perugia/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.